✨ Exciting news to start the new year! ✨ UNSW researchers have discovered how cells regulate the quality and quantity of a key RNA production process, which is key to their proper function and survival. Congratulations to Scott Berry, co-lead investigator from UNSW's School of Biomedical Sciences, the UNSW RNA Institute, and the EMBL Australia Node in Single Molecule Science, for his remarkable contribution to this research! Read the full story here: https://lnkd.in/gpazBb6a
UNSW RNA Institute
Higher Education
UNSW Sydney, New South Wales 1,250 followers
A world class science, therapeutics and translational facility for improving quality of life through innovations.
About us
The UNSW RNA Institute is Australia’s leading RNA science, therapeutics and translational facility. Established with a $25 million investment from UNSW Sydney as part of a NSW RNA Bioscience Alliance, a partnership across all universities in NSW and ACT, and the NSW Government-funded $15 million NSW RNA Production and Research Network. Together, we’re building a world-leading manufacturing capability in NSW that will yield jobs, skills, and innovation in an industry with the potential to transform lives. Recently we celebrated a milestone achievement of becoming Australia’s first ISO 9001 Certified RNA Pre-clinical scale Manufacturing Facility. To be the first in Australia to attain the internationally recognised ISO 9001 registration, proves UNSW RNA Institute’s commitment and dedication to product quality and reliability as a trusted provider of RNA-based therapeutics. The UNSW RNA Institute Accelerator, the pre-clinical scale manufacturing facility of the Institute, is pivotal in building up Australia’s own pipeline in RNA therapeutics. This facility will be able to accelerate current projects from around Australia to then utilise the $96m NSW Government funded RNA GMP Pilot facility in Sydney and other similar facilities that might be built in Australia in the near future. The ISO 9001 certified UNSW RNA Institute Accelerator is a perfect bridge between a number of developmental facilities around the country. Importantly, the emerging national network of facilities, the UNSW RNA Institute Accelerator and the Sydney-based RNA GMP facility will ensure that Australian researchers and innovators in the RNA therapeutics space are able to maximise the value of their own intellectual property onshore from discovery to the approved clinical product.
- Website
-
https://www.unswrna.institute
External link for UNSW RNA Institute
- Industry
- Higher Education
- Company size
- 11-50 employees
- Headquarters
- UNSW Sydney, New South Wales
- Founded
- 2022
Updates
-
Congratulations to UNSW RNA Institute academic members Dr Chantelle Ahlenstiel (Hood), Assoc Prof Zi Sophia Gu, Dr Daniel Fernandez-Ruiz, and Dr David Jacques for being awarded part of the $27 million in NHMRC Ideas and Development Grants! This funding will support their pioneering research in medicine, health, and engineering. Well done to all recipients! Read more here: UNSW awarded more than $27m for ideas and development research grants
UNSW awarded more than $27m for ideas and development research grants
unsw.edu.au
-
Congratulations to A/Prof Zi Sophia Gu from UNSW School of Chemical Engineering and UNSW RNA Institute on being selected as a recipient of the Pipeline Accelerator 2024-25 (Round 1)! Sophia's project on developing an mRNA nanoparticle formulation for low back pain treatment is one of the many exciting initiatives receiving support through this program.
*** Pipeline Accelerator Voucher Recipients Announced *** Therapeutic Innovation Australia (TIA), in partnership with Phenomics Australia and the National Deuteration Facility (NDF, ANSTO), is thrilled to announce the successful recipients of the Pipeline Accelerator 2024-25 (Round 1). Supported through the National Collaborative Research Infrastructure Strategy (#NCRIS), this initiative helps address the medical products challenge outlined in the 2021 National Research Infrastructure (#NRI) Roadmap. Together, TIA, NDF, and Phenomics Australia provide academic researchers and SMEs access to world-class Australian translational medical research infrastructure, spanning the molecular basis of health and disease through to clinical trials. This round, 37 projects, including one Technical Feasibility Assessment (TFA), will share a total of $1,263,387 in voucher awards with a total cash co-investment fund of $1,316,674, facilitating access to NRI to accelerate therapeutic translation and improve human health. Supported research areas includes Parkinson’s disease, epilepsy, oncology, and infectious diseases. These vouchers will subsidise a maximum of $50,000 of the total cost to access these translation NRIs. For TIA, this round marks a significant milestone, bringing the total number of awards over the 200 mark. This small scheme that started as a pilot in 2017 has now grown to become a fixture of the biotechnology landscape in Australia. The full list of awardees for the TIA Pipeline Accelerator and Therapeutic Feasibility Assessment 2024-25 (Round 1) can be found here: https://lnkd.in/gX7zxQZn Recipients affiliations: Griffith University | Neuromedicines Discovery Centre (NDC) Monash University | UQ Institute for Molecular Bioscience | The University of Queensland | Australian Regenerative Medicine Institute | Sid Faithfull Brain Cancer Laboratory QIMR Berghofer Medical Research Institute | Centre for Rare Diseases & Gene Therapy Centenary Institute | University of Sydney | Murdoch Children's Research Institute (MCRI) | Children's Medical Research Institute | Sydney Children's Hospitals Network | Translational Research Institute Australia | QUT (Queensland University of Technology) | The Kids Research Institute Australia | The Children’s Hospital at Westmead | School of Chemical Engineering UNSW | Cynata Therapeutics | exteRNA | The Florey Institute of Neuroscience and Mental Health | University of Melbourne | Hudson Institute of Medical Research | Monash Institute of Pharmaceutical Sciences | Fovero Therapeutics | Centenary Institute Life Sciences Queensland Ltd (LSQ)
-
-
The Micropore Technologies Ltd Pathfinder PRO 250 is officially up and running at the UNSW RNA Institute, driving the future of RNA therapeutics and vaccines. Dr Febrina Sandra, PhD working alongside Pete Davis (ATA Scientific).
Here it is!!! We are excited to share the news - Micropore Technologies Ltd Pathfinder PRO 250 is ready at the UNSW RNA Institute making next generation RNA therapeutics and vaccines - more to come...
-
-
-
-
-
+1
-
-
UNSW has secured over $41 million for 64 fundamental research projects in the latest round of Discovery Projects grants from the Australian Research Council. We are particularly proud to announce that five of these projects are led by distinguished academics from the UNSW RNA Institute. Congratulations to: A/Prof. Cecile King (with Robert Weatheritt & Thomas Gonatopoulos Pournatzis – Beyond virus sensing: Rig-like receptors in biomolecular condensates) Prof. Kate Quinlan (with Prof. Merlin Crossley & Gerd Blobel – Epigenetic readers guide transcription factors to their target genes) Prof. (John) Justin Gooding (with Minkyung Kand – Electrochemical Control of Fluorophore for Single-Molecule Light Microscopy) A/Prof. Zi (Sophia) Gu (with Siddulu Naidu Talapaneni – Engineering artificial organelles for on-demand bioenergy production) Prof. Cyrille Boyer (with Dipan Kundu, Priyank Vijaya Kumar, Jin Zhang, Nathaniel Corrigan, Vanessa Peterson and Jitendra Mata – 3D-Printing Nanostructured Solid Polymer Electrolytes) https://lnkd.in/giUd8Mdw
UNSW receives more than $41m for 64 ARC Discovery Projects
unsw.edu.au
-
Hitting the brain!
CRISPR brain delivery! I would be interested in what people think of this: Paper reports on delivery of a non-viral CRISPR-Cas (mRNA + guide RNA) to a fetal mouse brain. The key Innovation seems to be to use a high % of an acid degradable PEG. Could this work in people (even just adults)? Just nervous how risks relating to degradation products etc would pan out in people. Or should that be easily manageable? Great work from Murthy & Wang at UC Berkeley and Davis. #CRISPR #mRNA #LNP UNSW RNA Institute
Widespread Gene Editing in the Brain via In Utero Delivery of mRNA Using Acid-Degradable Lipid Nanoparticles
pubs.acs.org
-
Our team is excited to be part of the third annual conference of the Australasian RNA Biology and Biotechnology (A-RNA) in Melbourne! We’re eager to share our latest work in RNA therapeutics and connect with other innovators in the field. If you’re attending, drop by to learn more about our research and explore potential collaborations.
-
-
The UNSW RNA Institute is thrilled to be participating in BioJapan 2024, Asia's largest partnering event for the biotechnology and pharmaceutical industries. As a hub for cutting-edge research in RNA-based technologies, we look forward to connecting with global experts and innovators in drug development, diagnostics, and beyond. Join us as we shape the future of biotechnology. BioJapan 2024, 9-11 Oct, Yokohama – https://lnkd.in/ggQNjtWd Joshua Peterson (Chief Operating Officer) Andre Serobian (Chief Innovation & Commercialisation Officer) Hiroki Suyama (Scientist - RNA Analytics)
-
-
Reminder: Applications Now Open for 2024-25 Pipeline Accelerator & TFA Vouchers!
APPLICATIONS FOR PIPELINE ACCELERATOR AND TECHNICAL FEASIBILITY ASSESSMENTS (TFA) 2024-25 ROUND 1 VOUCHERS ARE NOW OPEN In this Pipeline Accelerator round, we continue to partner with two National Collaborative Research Infrastructure Strategy (NCRIS) organisations - Phenomics Australia and National Deuteration Facility (NDF) ANSTO, to expand the portfolio of services and expertise enabling medical research discovery and translation. This scheme aims to support therapeutic development projects by providing up to $50,000 with at least 50% matching funding (co-investment) by the applicant. We are pleased to announce the expansion of this scheme to include subsidised access to several new facilities, including GLP toxicology and preclinical research-grade viral vector production. 👉 Learn more here: https://lnkd.in/grjx9VWK We also provide support for TFAs for Cell & Gene Therapy (CGT) research projects. The TFAs will provide researchers with much needed direction for initiating translational research, building knowledge of the process and requirements and improving early-stage decisions. 👉 Learn more here: https://lnkd.in/g-47w5NC ⚠ Applications close 31st October, 5PM AEST ⚠ Info Session Join us on Tuesday the 10th of September at 1pm (AEST) for an info session. This webinar will outline how researchers from the public and private sectors can apply for vouchers to gain additional subsidised access to a range of services and expertise from several NCRIS facilities. These facilities offer expert advice, services and support for development of therapeutic products. 👉 REGISTER HERE: https://lnkd.in/gt4znhRd
-
-
RNA meets supramolecular peptide chemistry! And yes, it is not just about charge interactions!
Latest Preprint from our research: Arginine-rich peptides discriminate between purine- and pyrimidine-only RNA! Our latest preprint is out @ChemRxiv We also demonstrate how macromolecular crowding modulates RNA-peptide condensates. Congrats to Anika Moller, Isis Middleton, Grace Maynard & Hsiu Lin Li from Thordarson group & to Anna Wang on this achievement - it has been a fantastic collaboraiton. Do let us know if you have any comments on this work. UNSW RNA Institute School of Chemistry, UNSW Sydney #RNA #mRNA #ozchem #supramolecular https://lnkd.in/gHaCJpSF
-